Metrics as of 10/16/2026, 01:31 PM (Berlin time), refresh in progress.
MBX Biosciences Stock
MBX Biosciences, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steve Hoerter
- Employees
- 63
- Market cap
- $2.4 B
- IPO
- 13/09/2024
- Web
- mbxbio.com
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Headquartered in Carmel, Indiana, the company was founded in 2018. The company's pipeline includes several therapeutic candidates at…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
MBX Biosciences stock: price history
1D
+3.9%
1W
-4.8%
1M
-17.0%
6M
+52.6%
YTD
+60.8%
1Y
+263.5%
2Y
+110.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~12% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
MBX Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
MBX Biosciences is a clinical-stage biopharmaceutical company advancing the development of novel peptide therapies for endocrine and metabolic diseases. Its portfolio comprises various drug candidates at different stages of clinical testing: MBX 2109 for the treatment of chronic hypoparathyroidism is in Phase 2, while MBX 1416 is being developed against postoperative hypoglycemia (Phase 1). Another focus lies on MBX 4291, a GLP-1 and GIP co-agonist for the treatment of obesity, currently in the preclinical phase of IND studies. The business model aims at the commercialization of specialized therapeutics for chronic diseases.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about MBX Biosciences
Analyst assessment of MBX Biosciences
PRICE TARGET LOW
US$84.00
CONSENSUS
US$100.00
MEDIAN
US$88.00
PRICE TARGET HIGH
US$150.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 12/10/2026
MBX Biosciences stock metrics
P/E
-21.13
P/B
5.91
EV/EBITDA
-22.17
RETURN ON EQUITY
-9.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
43.5%
FLOAT SHARES
20,945,284
AVG. DAILY VOLUME (30D)
561,613
Insider transactions (SEC)
Azoulay Salomon
Smither John W
Hoerter Steven L.
Azoulay Salomon
Azoulay Salomon
Institutional holders
Comparable stocks
Frequently asked questions about MBX Biosciences stock
What does MBX Biosciences do?
MBX Biosciences, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steve Hoerter, the company employs around 63 people.
The IPO was on 13/09/2024; the stock trades on NASDAQ under the ticker MBX.
What do analysts say about MBX Biosciences stock?
7 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$100.00, ranging from US$84.00 to US$150.00, with a median of US$88.00.
This is an external assessment, not a statement by Market Jury.
When does MBX Biosciences report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -12% stronger than usual.
Does MBX Biosciences pay a dividend?
No, MBX Biosciences currently does not pay a dividend.
Which stocks are comparable to MBX Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MBX Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess MBX Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.